Hepatitis D Market Report 2026

Hepatitis D Market Overview

• Hepatitis D market size has reached to $0.76 billion in 2025 • Expected to grow to $0.93 billion in 2030 at a compound annual growth rate (CAGR) of 4.1% • Growth Driver: Rising Hepatitis B Prevalence Fuels Growth In The Market • Market Trend: Leading Companies Driving Innovation In Hepatitis D RNA Targeted Therapies • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hepatitis D Market?

Hepatitis D, also known as hepatitis delta, is a liver infection caused by the hepatitis D virus (HDV). It is considered the most severe form of viral hepatitis and occurs only in individuals who are already infected with the hepatitis B virus (HBV). Hepatitis D virus depends on hepatitis B virus for its replication and survival, making it a co-infection or superinfection. The main types of hepatitis D are acute and chronic. Acute hepatitis D is a sudden and severe liver infection caused by the hepatitis D virus, often resulting in rapid-onset symptoms and potential liver complications. It is diagnosed through various methods, including blood tests, elastography, liver biopsy, serologic testing, and other diagnostic techniques. Drugs for hepatitis D are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used by various end-users, including clinics, hospitals, and other healthcare facilities.

What Is The Hepatitis D Market Growth Forecast?

The hepatitis d market size is expected to see steady growth in the next few years. It will grow to $0.93 billion in 2030 at a compound annual growth rate (CAGR) of 4.1%. The growth in the forecast period can be attributed to increasing research into novel HDV treatments, rising focus on combination antiviral therapies, expansion of vaccination-linked prevention strategies, growing awareness in high-risk populations, increased investments in rare liver disease research. Major trends in the forecast period include increasing focus on early detection of co-infections, rising use of advanced serologic testing, growing demand for specialized treatment protocols, expansion of hospital-based disease management, enhanced focus on disease awareness.

What Is The Driver Of The Hepatitis D Market?

The increasing prevalence of hepatitis B is expected to propel the growth of the hepatitis D market going forward. Hepatitis B refers to a viral infection that affects the liver, causing symptoms such as jaundice, fatigue, and abdominal pain, and can lead to chronic liver disease or liver cancer if left untreated. The increase in Hepatitis B cases is attributed to factors such as unprotected sexual contact, sharing of needles, mother-to-child transmission during childbirth, and insufficient vaccination coverage in certain regions. Hepatitis D relies on the Hepatitis B virus for its replication, as it uses the surface antigen of Hepatitis B to infect liver cells, making the co-infection of both viruses a critical factor in the progression of liver disease. For instance, in April 2025, according to the Department of Health and Human Services, a US-based government department, there were 17,650 cases of newly reported chronic hepatitis B during 2023 and 1,769 hepatitis B-related deaths reported during 2023. Therefore, the increasing prevalence of hepatitis B is driving the growth of the hepatitis D industry.

Key Players In The Global Hepatitis D Market

Major companies operating in the hepatitis d market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol-Myers Squibb Company, Abbott Laboratories, GSK plc, Gilead Sciences Inc., Viatris Inc., VBI Vaccines Inc., Alnylam Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., Dynavax Technologies Corporation, Echosens S.A., Arbutus Biopharma Corporation, PROBIOMED SA de CV, Assembly Biosciences Inc., Replicor Inc., Eiger BioPharmaceuticals Inc., Bluejay Therapeutics Inc., Janssen Pharmaceuticals Inc., Transgene SA, Vir Biotechnology Inc., Biorex Diagnostics Ltd.

Global Hepatitis D Market Trends and Insights

Major companies operating in the hepatitis D market are focusing on developing innovative solutions such as RNA-targeted antiviral therapy to improve treatment outcomes and address unmet medical needs in chronic hepatitis D infection. RNA-targeted antiviral therapy refers to a treatment approach that directly targets the RNA of a virus to inhibit its replication, disrupt viral protein production, or silence viral genes, thereby reducing viral load and controlling infection. For instance, in December 2024, Vir Biotechnology Inc., a US-based biotechnology company, received both the U.S. Food and Drug Administration (FDA) Breakthrough Therapy designation and the European Medicines Agency (EMA) Priority Medicines (PRIME) designation for its combination therapy of tobevibart and elebsiran in treating chronic hepatitis delta (CHD).

What Are Latest Mergers And Acquisitions In The Hepatitis D Market?

In October 2023, Gilead Sciences Inc., a US-based biopharmaceutical company, partnered with Assembly Biosciences Inc., to advance the development of next-generation therapeutics. This collaboration aims to create innovative antiviral treatments for serious viral infections, including hepatitis B, herpesviruses, and hepatitis D. Assembly Biosciences Inc. is a US-based biotechnology company that focused on developing innovative small-molecule therapeutics to treat serious viral diseases, primarily targeting hepatitis B virus (HBV) and herpes viruses.

What Defines the Hepatitis D Market?

The hepatitis D market consists of revenues earned by entities by providing services such as clinical and diagnostic services, public health and awareness campaigns, research and development services, or treatment services. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatitis D market also includes sales of antiviral drugs, interferon therapies, nucleic acid polymers, liver transplant services, and diagnostic tests. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hepatitis D Market Report 2026?

The hepatitis d market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hepatitis d industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.